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Aims: At the time of diagnosis, 60% of lung cancer patients present with cachexia, a
severe wasting syndrome that increases morbidity and mortality. Tumors secrete multiple
factors that contribute to cachectic muscle wasting, and not all of these factors have
been identified. We used Orbitrap electrospray ionization mass spectrometry to identify
novel cachexia-inducing candidates in media conditioned with Lewis lung carcinoma
cells (LCM). Results: One-hundred and 58 proteins were confirmed in three biological
replicates. Thirty-three were identified as secreted proteins, including 14-3-3 proteins,
which are highly conserved adaptor proteins known to have over 200 binding partners.
We confirmed the presence of extracellular 14-3-3 proteins in LCM via western blot and
discovered that LCM contained less 14-3-3 content than media conditioned with C2C12
myotubes. Using a neutralizing antibody, we depleted extracellular 14-3-3 proteins in
myotube culture medium, which resulted in diminished myosin content. We identified
the proposed receptor for 14-3-3 proteins, CD13, in differentiated C2C12 myotubes
and found that inhibiting CD13 via Bestatin also resulted in diminished myosin content.
Conclusions: Our novel findings show that extracellular 14-3-3 proteins may act as
previously unidentified myokines and may signal via CD13 to help maintain muscle mass.
Keywords: cachexia, cancer, myosin, proteomics, skeletal muscle, 14-3-3 proteins
Introduction
Lung cancer kills more people each year than prostate, pancreatic, breast, and colon cancers
combined (Society, 2012). At the time of diagnosis, 60% of lung cancer patients have cachexia,
a severe wasting syndrome that includes loss of muscle mass, weakness, and fatigue (Fox
and Wang, 2007; Fearon et al., 2011; Society, 2012). This syndrome cannot be reversed by
nutritional interventions, diminishes response to and tolerance of cancer treatments, and increases
morbidity and mortality (Fearon et al., 2013). Over the last several decades, research has revealed
the complex and multifactorial nature of cachexia (Tan and Fearon, 2008; Blum et al., 2011;
Fearon et al., 2011; Tsoli and Robertson, 2013). Tumor- and host-derived inflammatory factors
stimulate degradation of myofibrillar proteins via signaling pathways, including up-regulation of
ubiquitin proteasome activity and autophagy (Romanello and Sandri, 2010; Fearon et al., 2013).
Abbreviations: : LCM, Lewis lung carcinoma conditioned medium; PAGE, polyacrylamide gel electrophoresis.
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In addition to increased protein degradation, protein synthesis
is also reduced, contributing to a net loss of muscle mass
(Gordon et al., 2013). The intracellular pathways leading to
muscle wasting have been widely studied; however, we know
less about the tumor-derived extracellular factors that alter the
balance between protein synthesis and degradation. Although
cachectic cytokines, such as TNF-α and IL-6, are elevated
in the sera of cancer patients, clinical trials with one-target
inhibitors have proven ineffective (Mantovani et al., 2013; Tsoli
and Robertson, 2013). These results confirm that no single
cytokine is responsible for cachexia, and suggest that there may
be unknown extracellular factors contributing to cancer-induced
muscle wasting. Identifying novel cachectic factors warrants
further study.
We chose to focus on identifying cachectic factors from lung
cancer because it accounts for 23% of all cancer deaths worldwide
(Jemal et al., 2011). Lewis lung carcinoma served as our cancer
model because it is known to induce cachexia both in vitro and
in vivo (Carbo et al., 2004; Argiles et al., 2008; Puppa et al.,
2014). One hundred and fifty eight proteins were identified by
mass spectrometry, and we focused on the 33 secreted proteins.
14-3-3 proteins in particular captured our attention: they are a
multi-functional and highly conserved family of binding proteins
with over 200 known partners (Freeman and Morrison, 2011;
Gardino and Yaffe, 2011; Kleppe et al., 2011; Obsil, 2011).
The seven isoforms of 14-3-3 proteins are routinely found
in the intracellular environment affecting signaling pathways
by altering enzymatic activity, protein-to-protein interactions,
cellular location, and protein stability (Freeman and Morrison,
2011; Gardino and Yaffe, 2011; Kleppe et al., 2011; Obsil, 2011;
Tzivion et al., 2011). Several recent studies have shown that
some isoforms, including 14-3-3η, 14-3-3σ, and 14-3-3α/β, act in
an extracellular manner to activate signaling cascades (Ghaffari
et al., 2010; Asdaghi et al., 2012; Maksymowych et al., 2014). We
found that depletion of extracellular 14-3-3 proteins decreased
myosin content in skeletal muscle. Extracellular 14-3-3 proteins




We plated C2C12myoblasts (American Type Culture Collection)
at a density of 10,000 cells/cm2 in growth medium [Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS), 1.6 g/L NaHCO3, and 100U/ml PenStrep
(Invitrogen)] and grew cells at 37◦C in 5% CO2. After 3
days, cells reached ∼90% confluence, and we serum-restricted
the cells in differentiation media (DMEM as above with 2%
horse serum replacing FBS). After 4 days in differentiation
media, multinucleated myotubes were ready for treatment.
Fresh medium was added every 2 days (Moylan et al.,
2014).
Cancer Cells
Lewis lung carcinoma cells (LL/2: American Type Culture
Collection) were seeded in 100mm cell culture plates in growth
medium (as above) at a density of 6000 cells/cm2. After 2 days,
we added supplementary growth media to each plate. LL/2 cells
contain a heterogeneous mix of adherent and floating cells.
After 4 days, we removed growth medium, and floating cells
were harvested by centrifugation at 500 × g, 5min. Pelleted cells
and 10mL differentiation media were added back to the plate
containing the adherent cells. After 2 days, conditioned media
were harvested and cleared of cells and debris by centrifugation
(500× g, 5min). Aliquots were frozen in liquid nitrogen for later
use. For myotube treatments, conditioned media were diluted
1 in 4 with fresh differentiation media. For mass spectrometry
analysis, serum-free media replaced differentiation media
(McLean et al., 2014).
Western Blot
We homogenized C2C12 myotubes in 2X protein loading buffer
(120mM Tris pH 7.5, 4% SDS, 200mM DTT, 20% glycerol,
0.002% bromphenol blue). Proteins were separated in equal
volumes of lysates by SDS-PAGE (4-15% Criterion, BioRad). We
determined relative total protein by scanning (Odyssey Infrared
Imaging, LI-COR) stained gels (Simply Blue, Invitrogen). We
used fluorescence intensity data to normalize total protein for
equal loading. SDS-PAGE was used to separate equal amounts
of protein, which was then transferred to PVDF membranes for
western blot using the Odyssey System (Moylan et al., 2014).
For conditioned media samples, we combined 6X loading buffer
(as above) 1:10 with conditioned media, and followed the same
procedure as for lysates.
Antibodies
For western blot, primary antibodies were mouse anti-myosin
(Sigma), rabbit anti-pan 14-3-3 (Cell Signaling), and rabbit
anti-CD13 (Abcam). Secondary antibodies included anti-mouse
IRDye 800 CW and anti-rabbit IRDye 800 CW (LI-COR). For
antibody neutralization experiments, we treated cell culture
medium with a 1:200 dilution of the primary antibody for
pan-14-3-3 or CD13, or the respective heat-inactivated control
for 48 h.
Fluorescence Microscopy and Width
Measurements
For width measurements, we incubated C2C12 myotubes with
nucleic acid stain, Syto13 (2.5µM, Invitrogen) for 15min.
We captured live-cell bright field and fluorescence images
(excitation: 488 nm, emission 509 nm) using a CCD camera
(CoolSNAP-ES, Roper Scientific Photometrics) attached to a
Nikon TE2000 microscope with NIS Elements image acquisition
software (Nikon). To obtain the average myotube width
per well, we measured 3 images per well, 5 myotubes per
image, and 5 width measurements per myotube. For CD13
immunofluorescence, myotubes were fixed in 100% methanol
cooled to −20C for 5min, after which they were blocked for
30min with Odyssey block buffer (LI-COR). After blocking,
we incubated cells with 1:250 dilution of rabbit anti-CD13
antibody (Abcam) overnight at 4C. After rinsing myotubes
3x, we incubated cells 1 h with 1:1000 secondary antibodies,
donkey anti-rabbit 649 (DyLight). We captured fluorescence
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FIGURE 1 | LCM-induced loss of myotube width. (A) Image of untreated myotubes. (B) Image of myotubes treated with LCM for 48 h. (C) Graph of width
changes in control and LCM-treated myotubes (mean ± SE, n = 6, repeated measures ANOVA, *P < 0.05).
images using the same system as above (excitation: 655 nm,
emission 670 nm). Fluorescence was measured with ImageJ
(NIH).
Proteomics
Mass spectrometric analysis was performed at the University
of Kentucky, Proteomics Core Facility. This core facility is
supported in part by funds from the Office of the Vice President
for Research. Cellular locations of identified proteins were
determined by database searches in Protein (NCBI) and UniProt
(UniProt Consortium).
Statistics
Prism 5.0b served as our statistics software (GraphPad Software).
We used ANOVA, or repeated measures ANOVA, with
Bonferroni post-test for multiple comparisons, and t-test for all
other comparisons. Data are presented as mean ± SE. Statistical
significance was defined as p < 0.05.
Results
LCM Treatment Induces Loss of Myotube Width
To confirm the efficacy of our in vitro muscle-wasting model,
we treated C2C12 myotubes with LCM and measured myotube
width.Wemeasured width before treatment and found that there
was no difference in average width between groups. After 48 h
of LCM treatment, we found that the average width in control
myotubes increased, while the average width in LCM-treated
myotubes decreased (Figures 1A–C).
LCM Treatment Decreases Total Protein and
Myosin Protein Content
Cancer cachexia is known to preferentially degrade the
myofibrillar protein, myosin (Acharyya et al., 2004; Banduseela
et al., 2007; Ochala and Larsson, 2008). To confirm this outcome
in our model, we treated myotubes for 48 h with LCM and
measured total protein and myosin content via western blot.
FIGURE 2 | LCM treatment decreases total protein and myosin in
C2C12 myotubes. 48 h of LCM treatment decreased (A) total protein by
14%, and (B) myosin content by 70% (mean ± SE n = 6, *P < 0.05, t-test).
Compared to control, LCM treatment caused a loss of total
protein and myosin (Figures 2A,B).
Proteins in Lewis Lung Cancer Conditioned
Media
Cancerous tumors secrete factors that alter their surrounding
environment. To investigate which tumor-derived proteins may
contribute to cancer cachexia, we used mass spectrometry to
examine three biological replicates of serum-free LCM. Mass
spectrometry identified 446 total proteins, with 158 confirmed
in all replicates (Figure 3A). We identified the cellular location
of the 158 confirmed proteins and found that 33 were secreted
(Figure 3B).
Extracellular 14-3-3 Proteins in LCM and their
Effect on Myosin Content
Our proteomics data showed that LCM contains all seven
isoforms of 14-3-3 proteins, but any effect of extracellular 14-3-3
proteins on skeletal muscle was unknown. Using an anti-pan14-
3-3 antibody, we assessed 14-3-3 content in media conditioned
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FIGURE 3 | Mass spectrometry results comparing protein distribution
in LCM.(A) Each circle represents one biological replicate of LCM and
compares the number of proteins that the replicates shared in common. (B)
Cellular location of the 158 proteins confirmed in LCM.
FIGURE 4 | 14-3-3 content and its effect on myosin. (A) Pan 14-3-3
content in C2C12-CM vs. LCM (mean ± SE n = 4, *P < 0.05, t-test). (B)
Myosin content decreased when extracellular 14-3-3 proteins were neutralized
in myotube cell culture medium using an anti-pan14-3-3 antibody (mean ±
SE, n = 4, *P < 0.05, ANOVA with Bonferroni post test).
with untreated C2C12 myotubes (C2C12-CM) and in LCM via
western blot. Compared to C2C12-CM, LCM contained less 14-
3-3 content (Figure 4A). To assess whether extracellular 14-3-3
proteins affect myosin content in skeletal muscle, we neutralized
14-3-3 proteins in myotube culture medium using an anti-
pan14-3-3 antibody. After 24 h, we examined myosin content
via western blot. Neutralizing extracellular 14-3-3 proteins
decreased myosin content compared to control myotubes, and
myotubes treated with heat-inactivated anti-pan14-3-3 antibody
(Figure 4B).
CD13 Receptor on C2C12 Myotubes and Adult
Skeletal Muscle
CD13 is the proposed receptor for some extracellular isoforms
of 14-3-3 (Ghaffari et al., 2010). CD13 is found on stem cells,
including myoblasts, but its presence on differentiated skeletal
muscle was not known (Ghosh et al., 2014; Rahman et al.,
2014a,b). Using an anti-CD13 antibody, we examined non-
permeabilized C2C12 myotubes for CD13 with a fluorescence
microscope, and found it present (Figure 5A).We also confirmed
FIGURE 5 | CD13 content is elevated in LCM-treated C2C12 myotubes
and LCM. (A) Image of anti-CD13 antibody using a fluorescence microscope.
(B) CD13 content in control vs. LCM-treated myotubes via western blot (mean
± SE, n = 6, *P < 0.05, t-test). (C) CD13 content in C2C12-CM vs. LCM
(mean ± SE, n = 4, *P < 0.05, t-test).
CD13 content inmyotubes via western blot.We found that LCM-
treated myotubes had higher CD13 content compared to control
(Figure 5B). Some pathologies show an increase in a soluble form
of CD13 in plasma (Van Hensbergen et al., 2002; Piedfer et al.,
2011; Wickstrom et al., 2011). Therefore, we tested CD13 content
in C2C12-CM vs. LCM via western blot and found that LCM
contained higher CD13 content (Figure 5C).
Aminopeptidase Inhibitor Decreases Myosin
Content in C2C12 Myotubes
Inhibiting the proposed receptor for extracellular 14-3-3 proteins
should have the same affect on myotubes as neutralizing 14-3-3
proteins. We treated myotubes with Bestatin, an inhibitor that
targets CD13 as well as aminopeptidase B and leukotriene A4
hydrolase. Using western blot, we found that 25µM Bestatin
decreased myosin content (Figure 6A). We also used an anti-
CD13 antibody in myotube culture medium to neutralize CD13,
but it did not affect myosin content (Figure 6B).
Discussion
Cachexia presents in 50% of all cancer patients and contributes
to 30% of all cancer deaths (Fox and Wang, 2007; Fearon,
2008; Tisdale, 2009). Efforts to identify the extracellular factors
that initiate cachexia are ongoing. The current consensus is
that cachexia syndrome is caused by multiple factors (Fearon
et al., 2011; Tsoli and Robertson, 2013). Several well-established
cachectic cytokines are elevated in the sera of cancer patients,
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FIGURE 6 | Inhibition of CD13 with Bestatin, but not antibody
neutralization, decreased myosin content in myotubes. (A) Western blot
comparing myosin content in control vs. Bestatin-treated myotubes (mean ±
SE, n = 7, *P < 0.05, t-test). (B) Western blot comparing myosin content in
control myotubes vs. myotubes for which CD13 was neutralized in myotube
culture medium or heat-inactivated CD23 antibody control (mean ± SE, n = 3,
n.s., ANOVA).
including TNF-α, IL-6, and myostatin (Barton, 2001; Jespersen
et al., 2006; Kayacan et al., 2006; White et al., 2013; Lokireddy
et al., 2015). However, clinical trials for single-target inhibitors
fail to fully alleviate muscle wasting (Mantovani et al., 2013; Tsoli
and Robertson, 2013). These results suggest that unidentified
factors may also be involved. Our goal was to identify new
candidates that may contribute to muscle wasting. Our novel
findings also show that: extracellular 14-3-3 proteins have a
role in muscle maintenance; CD13 is present on differentiated
skeletal muscle; and CD13 may act as the receptor for 14-3-3
proteins.
We began by validating our model using myotube size as a
morphological endpoint, and myosin as the molecular endpoint.
Myosin was chosen because it is preferentially degraded in
cachexia, and as the major contractile protein in skeletal muscle,
its loss can depress respiratory function, diminish strength,
and increase fatigue (Acharyya et al., 2004; Du et al., 2004; Li
et al., 2005; Tisdale, 2005; Zhang et al., 2011; Johns et al., 2013;
Chacon-Cabrera et al., 2014). We confirmed that LCM treatment
reduced size, total protein, and myosin content in myotubes
(Figures 1, 2); (Acharyya et al., 2004; Du et al., 2004; Banduseela
et al., 2007; Ochala and Larsson, 2008; Yano et al., 2008; Zhang
et al., 2011; Goncalves et al., 2013; Stacchiotti et al., 2014).
After establishing our model, we began identifying proteins
in LCM.
Using mass spectrometry, we confirmed 158 proteins,
including 33 secreted proteins (Figures 3A,B). Some proteins
identified derived from intracellular compartments, a common
occurrence in proteomic studies using conditioned media
(Huang et al., 2006; Kim et al., 2008; Sardana et al., 2008;
Planque et al., 2009; Yousefi et al., 2012). Due to high sensitivity
of mass spectrometry, contents from the few cells that die
during cell culture are identified. Alternatively, some intracellular
proteins may be secreted via exosomes and are identified in
conditioned media (Gross and Boutros, 2013; Raposo and
Stoorvogel, 2013; Shimoda and Khokha, 2013; Aoi and Sakuma,
2014). Of the 33 secreted proteins, we identified 14-3-3 proteins
as a promising cachexia-inducing candidate because they are
involved in multiple signaling pathways and have over 200
known binding partners.
14-3-3 proteins are multi-functional and highly conserved
binding proteins (Freeman and Morrison, 2011; Gardino and
Yaffe, 2011; Kleppe et al., 2011; Obsil, 2011). They include
seven isoforms, which are routinely found in the intracellular
environment affecting diverse signaling pathways such as
metabolism, growth, and apoptosis (Freeman and Morrison,
2011; Gardino and Yaffe, 2011; Kleppe et al., 2011; Obsil,
2011). However, several recent studies have shown that some
isoforms act in an extracellular manner to activate signaling
cascades. Maksymowych et al. reported that extracellular
14-3-3η was elevated in patients with rheumatoid arthritis
(RA). THP-1 cells treated with 14-3-3η showed increased
phosphorylation of ERK1/2 and JNK/SAPK and increased
production of inflammatory transcripts, IL-1β, IL-6, and MMP-
1 (Maksymowych et al., 2014). In another study, Ghaffari et al.
found that extracellular 14-3-3σ increased MMP-1 content in
fibroblasts (Ghaffari et al., 2010). Similarly, Asdaghi et al. found
that extracellular 14-3-3α/β induced MMP-1 transcript in lung
fibroblasts (Asdaghi et al., 2012). Notably, they also found that
media conditioned with lung cancer cell line, A549, and its
control, bronchial epithelial cell line HS24, both contained 14-
3-3α/β; however, the results for each cell line were presented
separately, making it impossible to compare extracellular 14-3-3
content.
In our study, we compared 14-3-3 content between LCM
and C2C12 myotube conditioned media. When we confirmed
the presence of 14-3-3 proteins in LCM via western blot, we
found that LCM contained lower pan14-3-3 content than C2C12-
CM (Figure 4A). In order to determine whether depletion of
extracellular 14-3-3 content might contribute to cachexia, we
treated myotube culture media with an anti-pan14-3-3 antibody.
Neutralization of extracellular 14-3-3 proteins decreased myosin
content in myotubes (Figure 4B). These data suggest that
extracellular 14-3-3 proteins are necessary for maintaining
myosin content in skeletal muscle, however a receptor for
extracellular 14-3-3 proteins in skeletal muscle was unknown.
Previous work by Ghaffari et al. in fibroblasts showed that
CD13 may act as the receptor for some isoforms of 14-3-
3. In their 2010 study, the authors used immunofluorescence
microscopy and found that 14-3-3σ co-localized with CD13
(Ghaffari et al., 2010). CD13 is found on many types of
stem cells, including skeletal muscle satellite cells (Rahman
et al., 2014a,b). Using an animal model of ischemic hind-
limb injury, Rahman et al. found that CD13KO had impaired
muscle regeneration compared to WT control mice (Rahman
et al., 2014a). These findings showed that CD13 is present on
muscle satellite cells and that it affects skeletal muscle, but its
presence on differentiated skeletal muscle was unknown. Using
immunofluorescence microscopy, we confirmed the presence
of CD13 on differentiated skeletal muscle, which is in itself a
novel finding (Figure 5A). Our results also showed that LCM
treatment increased CD13 content in myotubes (Figure 5B).
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Van Hensbergen et al. found elevated soluble CD13 (sCD13)
in the plasma of cancer patients, and suggested that tumors
shed CD13 from the plasma membrane (Van Hensbergen et al.,
2002). When we examined LCM vs. C2C12-CM for sCD13, we
found that LCM contained elevated sCD13 content (Figure 5C).
These novel data confirm the presence of CD13 on differentiated
skeletal muscle and in conditioned media from both lung tumors
and skeletal muscle. We speculate that sCD13 may bind 14-3-3
proteins in the samemanner that soluble TNFα receptors capture
TNFα: soluble CD13 may be the mechanism for extracellular
14-3-3 depletion.
With the presence of CD13 confirmed in differentiated
myotubes, we treated myotubes with Bestatin, a potent
aminopeptidase inhibitor, to determine if CD13 is the receptor
for 14-3-3 proteins in skeletal muscle. In theory, CD13
inhibition should affect skeletal muscle in the same manner
as depletion of 14-3-3 proteins. In fact, 25µM Bestatin did
decrease myosin content, which to our knowledge is a novel
finding (Figure 6A). These results show that aminopeptidases
are involved in skeletal muscle maintenance, but as Bestatin
has multiple targets, we needed to inhibit CD13 specifically.
However, CD13 neutralization using an anti-CD13 antibody did
not affect myosin content (Figure 6B). Interestingly, Ghaffari
et al. had the opposite result: when they used Bestatin to inhibit
the effects of extracellular 14-3-3σ via CD13, it had no effect
(Ghaffari et al., 2010). Their results may indicate that CD13
is not the receptor for 14-3-3σ despite co-localization, or, as
the authors suggested, that the site of CD13 enzymatic action
regarding MMP-1 may be at an alternate site from that which
Bestatin targets. There are several epitopes on CD13 targeted by
different monoclonal antibodies (Xu et al., 1997; Mina-Osorio,
2008; Piedfer et al., 2011). It is possible that the antibody we used
labeled CD13 without affecting the site where 14-3-3 proteins
bind.
Conclusions
Extracellular 14-3-3 proteins appear to have a role in maintaining
skeletal muscle mass, and some isoforms may act as previously
unidentified myokines. CD13 is a candidate receptor for 14-
3-3 proteins, and its soluble form may be the mechanism for
14-3-3 diminishment in LCM. Future studies should include
determining which individual isoforms of 14-3-3 act in the
extracellular space to affect skeletal muscle mass, and what role
soluble CD13 plays in differentiated skeletal muscle. This study
proposes a role for extracellular 14-3-3 proteins in skeletal muscle
and is an initiating point for future studies delineating this
previous unidentified pathway.
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